OPTINOSE
NASDAQ: OPTN (OptiNose, Inc.)
Last update: 12 minutes ago6.55
-0.14 (-2.02%)
| Previous Close | 6.68 |
| Open | 6.81 |
| Volume | 39,048 |
| Avg. Volume (3M) | 54,943 |
| Market Cap | 65,811,940 |
| Price / Sales | 0.730 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2025 - 10 Mar 2025 |
| Profit Margin | -41.16% |
| Operating Margin (TTM) | -10.04% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | 3.10% |
| Current Ratio (MRQ) | 0.510 |
| Operating Cash Flow (TTM) | -35.23 M |
| Levered Free Cash Flow (TTM) | -23.07 M |
| Return on Assets (TTM) | -10.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | OptiNose, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | -5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 6.21% |
| % Held by Institutions | 78.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fmr Llc | 30 Sep 2024 | 1,102,845 |
| Mvm Partners, Llc | 30 Sep 2024 | 973,733 |
| Nantahala Capital Management, Llc | 30 Sep 2024 | 957,161 |
| Great Point Partners I Lp | 30 Sep 2024 | 857,452 |
| Rosalind Advisors, Inc. | 30 Sep 2024 | 552,528 |
| Stonepine Capital Management, Llc | 30 Sep 2024 | 379,258 |
| Kingdon Capital Management, L.L.C. | 30 Sep 2024 | 373,301 |
| D. E. Shaw & Co., Inc. | 30 Sep 2024 | 333,350 |
| Bleichroeder Lp | 30 Sep 2024 | 269,689 |
| Vanguard Group Inc | 30 Sep 2024 | 256,969 |
| Massachusetts Financial Services Co /Ma/ | 30 Sep 2024 | 205,053 |
| Easterly Investment Partners Llc | 30 Sep 2024 | 157,290 |
| Velan Capital Investment Management Lp | 30 Sep 2024 | 143,114 |
| Geode Capital Management, Llc | 30 Sep 2024 | 86,560 |
| Prescott Group Capital Management, L.L.C. | 30 Sep 2024 | 83,477 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (HC Wainwright & Co., -23.61%) | Buy |
| Median | 3.00 (-54.16%) | |
| Low | 1.00 (Piper Sandler, -84.72%) | Buy |
| Average | 3.00 (-54.16%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 5.00 (-23.61%) | Buy | 7.61 |
| Piper Sandler | 13 Nov 2024 | 1.00 (-84.72%) | Buy | 7.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Dec 2024 | Announcement | Optinose Announces 1-for-15 Reverse Stock Split |
| 02 Dec 2024 | Announcement | Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference |
| 12 Nov 2024 | Announcement | Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights |
| 05 Nov 2024 | Announcement | Optinose Announces Reporting Date for Third Quarter 2024 Financial Results |
| 16 Oct 2024 | Announcement | Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Oct 2024 | Announcement | Optinose Appoints Terry Kohler as Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |